Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
NM-5072 by NovelMed Therapeutics for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval
NM-5072 is under clinical development by NovelMed Therapeutics and currently in Phase I for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData,...